GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MNKKQ) » Definitions » Net Issuance of Preferred Stock

Mallinckrodt (Mallinckrodt) Net Issuance of Preferred Stock : $0 Mil (TTM As of Sep. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Mallinckrodt Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Mallinckrodt's net issuance of preferred for the three months ended in Sep. 2023 was $0 Mil. The number is 0, which means that Mallinckrodt has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Mallinckrodt's net issuance of preferred for the trailing twelve months (TTM) ended in Sep. 2023 was $0 Mil.


Mallinckrodt Net Issuance of Preferred Stock Historical Data

The historical data trend for Mallinckrodt's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Net Issuance of Preferred Stock Chart

Mallinckrodt Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mallinckrodt Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mallinckrodt Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mallinckrodt Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Mallinckrodt (Mallinckrodt) Business Description

Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
Sigurdur O Olafsson director, officer: President and CEO 360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Myers Woodrow A Jr director 1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Fyi S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Ffi Iii S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Olifant Luxco S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Daniel Arthur Celentano director 2831 S. BAYSHORE DRIVE, UNIT 2103, MIAMI FL 33133
Riad Hussein El-dada director 910 TALAMORE DRIVE, AMBLER PA 19002
Bracebridge Capital, Llc 10 percent owner 888 BOYLSTON STREET, SUITE 1500, BOSTON MA 02199
Kassie Harrold officer: Chief Compliance Officer C/O MALLINCKRODT PHARMACEUTICALS, 675 MCDONNELL BLVD., HAZELWOOD MO 63042
Neal P Goldman director 10700 PARKRIDGE BLVD., RESTON VA 20191
Steven J. Romano officer: EVP & Chief Sci. Ofcr 675 MCDONNELL BLVD., HAZELWOOD MO 63042
David Y Norton director 8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Carlos V Paya director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James R Sulat director

Mallinckrodt (Mallinckrodt) Headlines

From GuruFocus